Navigation Links
Test for early detection of prostate cancer shows promise

In the first clinical study of a new blood protein associated with prostate cancer, researchers have found that the marker, called EPCA or early prostate cancer antigen, can successfully detect prostate cancer in its earliest stages. At the same time, the marker successfully avoids the problem of false positive results that plagues prostate-specific antigen (PSA) testing.

Study results appear in the May 15, 2005, issue of Cancer Research. The lead author is Robert H. Getzenberg, Ph.D., professor of urology and director of research at the James Buchanan Brady Urological Institute at Johns Hopkins.

The traditional two-step approach of PSA testing and digital rectal examination has helped doctors identify prostate tumors early, while the cancers can still be cured. But PSA testing, like many disease-screening procedures, misses some cases of cancer and in other cases erroneously highlights noncancerous conditions.

“This new blood test, when coupled with PSA screening, may help reduce the number of both unnecessary biopsies and undetected prostate tumors,?said Getzenberg, In addition to being highly sensitive to prostate cancer, the EPCA test is also very specific to it, meaning that other cancers and benign prostate conditions are not detected, thus boosting doctors?confidence that a positive EPCA test is really a sign of prostate cancer, added Getzenberg.

“Once this test is refined and approved for general use, it will have an impact on the detection and treatment of prostate cancer,?said Getzenberg.

For the current study, Getzenberg and colleagues developed a simple test that would detect EPCA in the blood and then measured the EPCA levels in 46 patients, including those with prostate cancer (12 patients), bladder cancer (six patients), colon cancer (two patients), kidney cancer (one patient), spinal cord injury (seven patients) and noncancerous prostate inflammation (two patients), and 16 healthy individuals. The study was cond
'"/>

Source:Johns Hopkins


Page: 1 2

Related biology news :

1. UCSB scientists probe sea floor venting to gain understanding of early life on Earth
2. Neuronal traffic jam marks early Alzheimers disease
3. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
4. In the migratory marathon, parasitized monarchs drop out early
5. PET/CT can identify new cancer lesions at early stage, allowing for prompt treatment
6. Confocal imaging promises early detection of skin cancer
7. Measles Deaths Worldwide Drop By Nearly 40% Over Five Years
8. Oldest cranial, dental and postcranial fossils of early modern European humans confirmed
9. A whole lot of shaking goin on triggers early hatching in red-eyed tree frogs
10. New mitochondrial DNA gene chip may be early cancer diagnosis tool
11. MicroRNA tweaks protein that controls early heart development
Post Your Comments:
(Date:7/8/2008)...o stay fit, do their bit for the environment or av...eir health if they don,t choose the right bicycle....al surgeon Mr Vinod Nargund from St Bartholomew,s ...rnal BJU International . , He says that the pro...ection problems and soreness and skin irritations ...
(Date:7/8/2008)... . , Barcelona, Spain: Couples who need IVF... this will not lead to developmental problems in e...ual conference of the European Society of Human Re...Dr. Karin Middelburg, from the University Medical ... that the study, which looked at the quality of ge...
(Date:7/8/2008)... . , Barcelona, Spain: Children born after ...omb have higher birth weight than those born where...ed to the 24th annual conference of the European S...(Tuesday 8 July). The mothers had longer pregnanci...k of congenital malformations, said Dr. Anja Pinbo...
(Date:7/7/2008)...U.S. coral reef ecosystems are considered to be in...A analysis of the health of coral reefs under U.S....tate of Coral Reef Ecosystems of the United States...that the nation,s coral reef ecosystems, particula... face intense human-derived threats from coastal d...
Breaking Biology News(10 mins):Male cyclists risk sexual problems if they don’t choose the right bike 2IVF does not increase risk of developmental disorders in children 2Children born from frozen embryos weigh more and do better than those born after fresh transfer 2NOAA report states half of US coral reefs in 'poor' or 'fair' condition 2New insight into RA patient priorities and motivators for clinical trial involvement 21796 1New insight into RA patient priorities and motivators for clinical trial involvement 21796 2New insight into RA patient priorities and motivators for clinical trial involvement 21796 3Express Scripts in Binding Agreement with MSC for the Purchase of its Pharmacy Services Division 21792 1Express Scripts in Binding Agreement with MSC for the Purchase of its Pharmacy Services Division 21792 2Express Scripts in Binding Agreement with MSC for the Purchase of its Pharmacy Services Division 21792 3Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 1Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 2Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 3Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 4Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 5Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 6Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 7Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 8Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 9Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 10Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 11Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 12Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 13Patients Taking Cymbalta 28R 29 Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 2421 1Patients Taking Cymbalta 28R 29 Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 2421 2Patients Taking Cymbalta 28R 29 Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 2421 3Patients Taking Cymbalta 28R 29 Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 2421 4Patients Taking Cymbalta 28R 29 Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 2421 5
...at the Johns Hopkins Bloomberg School of Public He...r a variety of illnesses using genetically modifie...ctions. Oral adenovirus vaccines have long been pr...ieve their process for constructing a replicating ...nomical vaccines that provide longer-lasting disea...
...eport today in the journal Genome,Research that th...eviously intractable DNA sequence: a 554-kilobase-...man Y chromosome. This sequence,contains eight put...ex-associated height differences and gonadal tumor...f the few holes remaining in the,"finished" sequen...
...ave discovered that a protein that was originally ... resistance is actually a "missing enzyme" from th...cteria to scavenge iron. , The research appears as...he Journal of Biological Chemistry, an American So...al. , Mycobacterium tuberculosis, the causative a...
...pment in the analysis of cancer,has been announced... an,innovative method that enables the rapid advan... in cancer. According to the report,published in t...he,National Academy of Science (PNAS) in collabora...tute, Agilent has developed a specialised,microarr...
Other Biology News:Live Recombinant Adenovirus Vaccine Technique Explored 2Found: Missing sequence of the human Y chromosome 2Found: Missing sequence of the human Y chromosome 3Scientists find missing enzyme for tuberculosis iron scavenging pathway 2Breakthrough Microarray-based Technology for the Study of Cancer 2
(Date:7/8/2008)...IN FALLS, Ohio, July 8 /- Knowledge E...s announced today the release of The,2007-2008 Ort...ce for,objective, accurate, strategically oriented...summarizes the global orthopaedic market through,s...epair, Arthroscopy/Soft,Tissue Repair, Spinal Impl...
(Date:7/8/2008)...rgan-specific MRI Contrast Agent Approved in the U...n a Decade, WAYNE, N.J., July 8 /- B...diagnostic imaging, announced today that the U.S. ...VIST(R) (Gadoxetate Disodium),Injection, a gadolin...1-weighted magnetic resonance imaging (MRI) of the...
(Date:7/8/2008)...d and Management Focused on Near-Term Milestones a...Strategy, VANCOUVER and SAN DIEGO, July 8 /PRNews...FF), a clinical-stage developer of drugs for infec...pecial meeting of shareholders,for the purpose of ...(see,"Requisition of Shareholder Meeting"). Manage...
(Date:7/8/2008)... TechCFO, a leading provider of ou...es for technology and biotechnology companies, tod...rtner to its Boston office. Strickland is the late...ion, which opened in May of last year. , ... -- TechCFO, a leading provider of outsourced CFO...
Breaking Biology Technology:Knowledge Enterprises, Inc. and The Institute for Orthopaedics(TM) Release The 2007-2008 Orthopaedic Industry Annual Report 2FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 2FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 3FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 4FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 5FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 6FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 7MIGENIX Corporate Update and Requisition of Special Meeting 2MIGENIX Corporate Update and Requisition of Special Meeting 3MIGENIX Corporate Update and Requisition of Special Meeting 4MIGENIX Corporate Update and Requisition of Special Meeting 5MIGENIX Corporate Update and Requisition of Special Meeting 6MIGENIX Corporate Update and Requisition of Special Meeting 7MIGENIX Corporate Update and Requisition of Special Meeting 8TechCFO Adds Gary Strickland as Partner in Boston Office 2
...eviously reported initiative to establish a citywi...communities of Waukesha, Wauwatosa and Brookfield ...a are already being pitched by Cellnet, the provid...Milwaukee,s network is being built by a different ...stablished so far, the city is essentially leasing...
...student Pengpeng Zhang successfully imaged a piece... centimeter-in thickness, she and her UW-Madison c...ed thinking, the feat should be impossible because...ct electricity. , ,"After she did it, we realized,... thinner than what people normally use," says UW-...
... Third Wave Technologies has settled with a Belg...ng patents. Third Wave will license hepatitis C vi...ndisclosed financial terms. , ,The two companies, ... Wave forged a deal under which Innogenetics was a... line of products in Europe. It was Third Wave,s f...
... First Business Bank plans to launch a remote di...ne County. , ,Companies that purchased the service...over the Internet to the bank, where they would be... that First Business Bank president and COO Michae...c markets. , ,The service would eliminate trips to...
Other Biology Technology:Study explains unexpected conductivity of nanoscale silicon 2Study explains unexpected conductivity of nanoscale silicon 3
UBN-1 (C-20)
Rabbit polyclonal to Neuron navigator 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide conjugated to KLH derived from within residues 1850 to the C-terminus of Mouse Neuron
Mouse HAI-1 Ectodomain MAb (Clone 199732)
pETDuet-1 is designed for the coexpression of two target genes.
Biology Products: